Cellectar Biosciences Secures Funding to Accelerate Next-Generation Cancer Therapies

Cellectar Biosciences, Inc., a trailblazer in late-stage clinical biopharmaceutical innovation, is excited to share a recent funding announcement—a strategic milestone underscoring our commitment to advancing the next generation of cancer cell-targeting treatments. In this round, the company raised 0 dollars, a figure that reflects our decision to strategically reinvest internal resources and existing capital to further support our ambitious research and development agenda. Focused on revolutionizing cancer therapy, Cellectar Biosciences leverages its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform, which promises to deliver enhanced efficacy with improved safety profiles by minimizing off-target effects. Despite the nominal external funding in this instance, our financial strategy has been meticulously designed to spur progress on our diverse product pipeline, including the lead asset iopofosine I-131—a small-molecule PDC engineered to provide targeted delivery of the radioisotope iodine-131—as well as other promising preclinical PDC chemotherapeutic programs and partnered assets. The funds, internally allocated, are purposefully directed towards advancing pivotal preclinical and clinical trials, strengthening our research and development efforts, and fostering strategic collaborations that enhance our therapeutic reach. Our decision to capitalize on internal financing not only demonstrates our confidence in the science behind our innovative therapies but also reinforces our unwavering dedication to addressing unmet medical needs in oncology. For a deeper look into our groundbreaking work and future outlook, please visit www.cellectar.com or join the conversation by following us on Twitter, LinkedIn, Instagram, YouTube, and Facebook.